Skip to main content

Table 1 Specificities of receptor tyrosine kinase inhibitors

From: Anti-tumor innate immunity activated by intermittent metronomic cyclophosphamide treatment of 9L brain tumor xenografts is preserved by anti-angiogenic drugs that spare VEGF receptor 2

IC50s VEGFR1 (nM) VEGFR2 (nM) VEGFR3 (nM) PDGFR (nM) c-kit (nM) Refs
Axitinib 0.1 0.06-0.1 (0.25) 0.1-0.3 3-30 1-2 [31]
AG-028262 ~0.1 <1 (0.34) ~0.1-0.3 193   [39, 40]
Cediranib (AZD2171) 5 <1 (~0.5) <1-3 5 2 [32]
Sorafenib ~26 15-90 ~10-30 ~10-30 68 [30, 33]
  1. Shown are IC50 values reported in the indicated references for inhibition of each human receptor protein. IC50 values for inhibition of mouse VEGFR2 are shown in parenthesis.